louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06723821: Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain
Official title: Effectiveness of Noninvasive Neuromodulation in Post-COVID Musculoskeletal Pain in the Short Term: Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: COVID-19
Musculoskeletal Pain
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2024-12-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Brief Summary:

The post-Covid syndrome is a problem that affects a significant number of people in the world. Among the most common symptoms is pain, and although there is no specific data on neuropathic pain and Covid, due to under-diagnosis, they may be closely related.

Non-invasive neuromodulation acts on the Central Nervous System through the bioelectrical stimulation of nervous tissue and modulation of the system nervous, and can be useful in acute, chronic and musculosqueletal pain, and in symptoms such as stress, anxiety and sleep disturbances.

The objective of this clinical trial is to assess the efficacy of non-invasive neuromodulation in the treatment of post-Covid musculoskeletal pain. Subjects will be randomly divided into two groups: an experimental group in which non-invasive neuromodulation will be applied and a sham group to which it will be applied off. The variables to be studied before, during and after treatment will be neuropathic pain with the DN4 questionnaire, pain intensity with the EVA scale, sleep quality with the Pittsburgh Sleep Quality Index, level of stress and anxiety with the HADS questionnaire and quality of life with the SF12.


Eligibility criteria: Inclusion Criteria:

* Positive result in PCR or antigen test for detecting COVID-19 in the last 3 months.
* Present musculoskeletal pain in the last 3 months.
* Age between 18 to 65 years old.
* Score equal or superior to 4 in DN4 scale.

Exclusion Criteria:

* Present musculoskeletal pain of traumatic origin or known cause
* Present musculoskeletal pain with more than 3 months of evolution.
* Pregnant women
* Present of vascular alterations, malignancy, thrombophlebitis or fever.

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: Change from Baseline at one month.
Secondary outcomes:
measure: DN4 scale
timeFrame: Change from Baseline at one month.
measure: Pittsburg Sleep Quality Index score
timeFrame: Change from Baseline at one month.
measure: Hospital Anxiety and Depression Scale (HAND)
timeFrame: Change from Baseline at one month
measure: Quality of life SF12
timeFrame: Change from Baseline at one month.
Other outcomes:
Locations:
city: Alcalá De Henares
country: Spain
facility: Centro Investigación Fisioterapia y Dolor
state: Madrid
Study officials:
affiliation: Alcala University
name: Daniel Pecos-Martin, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02417584: Efficacy of PAP Therapy on Blood Pressure
Official title: The Role of Compliance With Positive Airway Pressure Use on Blood Pressure in Patients With Obstructive Sleep Apnea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnoea
Lead sponsor: University of Crete
Sponsor class: OTHER
First posted: 2015-04-15
Enrollment: 1168
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the study was to determine the long term effects of compliance with positive airway pressure therapy on blood pressure in both hypertensive and normotensive patients with obstructive sleep apnoea hypopnoea syndrome.

Detailed description: Scientific data about the causal role of obstructive sleep apnoea hypopnoea syndrome (OSAHS) in the development of systemic hypertension and the effects of positive airway pressure (PAP) treatment on blood pressure (BP) control are continuously increasing; however they are controversial. We aimed to determine the long term effects of compliance with PAP therapy on BP in both hypertensive and normotensive patients with OSAHS.

Eligibility criteria: Inclusion Criteria:

* newly diagnosed OSAHS by polysomnography according to standard criteria
* no history of previous PAP therapy
* normotensive and hypertensive patients
* an above-elementary school education.

Exclusion Criteria:

* refusal to participate
* refusal of PAP therapy
* secondary hypertension
* central sleep apnea syndromes
* obesity hypoventilation syndrome
* restrictive ventilator syndromes
* history of established cardiovascular disease
* severe congestive heart failure
* a history of life-threatening arrhythmias
* severe cardiomyopathy
* significant chronic kidney disease
* long-term oxygen therapy
* family or personal history of mental illness
* drug or alcohol abuse
* severe cognitive impairment
* concurrent oncological diseases
* need for chronic use of medication that may affect BP levels
* pregnancy
* history of narcolepsy or restless leg syndrome

Primary outcomes:
measure: drop in blood pressure
timeFrame: two years
Secondary outcomes:
Other outcomes:
Locations:
city: Heraklion
country: Greece
facility: Sleep Disorders Center, Department of Thoracic Medicine, University of Crete,
Study officials:
affiliation: University of Crete
name: Sophia E Schiza, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00164684: Men of Color Fatherhood Education and Violence Prevention Project
Official title: Men of Color Fatherhood Education and Violence Prevention Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Spouse Abuse
Keywords: batterers
prevention
African American
Latino
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-14
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A 16 session curriculum, developed for noncustodial African American and Latino fathers to improve knowledge, attitudes and skills and enable participants to remain non-violent towards their partners will be evaluated.


Eligibility criteria: Inclusion Criteria:

* Noncustodial fathers
* African American or Latino
* At high risk for violence (prior perpetration, un/underemployment)

Exclusion Criteria:

* Substance abusers

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Public Health Commission
state: Massachusetts
Study officials:
affiliation: Boston Public Health Commission
name: John Rich, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05037084: Activity and Health in Nursing Homes
Official title: The Association Between Physical Behavior, Sleep and Neuropsychiatric Symptoms in Nursing Homes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Old Age
Frailty
Keywords: Nursing home
Physical activity
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Trondheim Kommune
First posted: 2021-09-08
Enrollment: 1123
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All residents living full time in nursing homes. These are often frail older adults with reduced physical function, high number of medications and comorbidities.

Brief summary: There is expected to be an increased need for full time nursing homes as the increase in number of older adults increases and the rate of dementia diagnosis happens simultaneous with the decrees of healthcare personnel the years to come. A lift in knowledge is needed to provide a better and more efficient healthcare to be better equipped to meet this societal challenge. Physical activity and sleep are important indicators of health, but also on effect of treatment and care for this frail population. Comprehensive mapping of personnel time spent on different tasks and older adults' physical function throughout a week gives a unique opportunity to gain new knowledge about everyday life in nursing homes. The main aim of this project is to describe associations between physical behavior, sleep and symptoms in residents in nursing homes in Trondheim Municipality and combine these with personnel time spent on different working tasks.


Eligibility criteria: Inclusion Criteria:

All residents in nursing homes in Trondheim Municipality.

Exclusion Criteria:

Terminal residents or residents that can not stand or walk a few steps independently.

Primary outcomes:
measure: Axivity accelerometer
timeFrame: 7 days
measure: Somnofy sleepmonitor
timeFrame: 7 days
measure: Short Physical Performance Battery (SPPB)
timeFrame: Baseline
Secondary outcomes:
measure: Time register
timeFrame: 7 days
measure: Neuropsychiatric Inventory (NPI)
timeFrame: Baseline
measure: Dementia Staging Instrument (CDR)
timeFrame: Baseline
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: Trondheim Kommune
Study officials:
affiliation: Trondheim Kommune
name: Ingrid Olsen
role: STUDY_CHAIR
References:
Clinical trial NCT03072784: Aortic Cross Clamping Time, and Postoperative Respiratory Function
Official title: Implication of Aortic Cross Clamping Time Upon Postoperative Respiratory Function in Adult Patients Undergoing Open Heart Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bypass Complication
Respiratory Complication
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-03-07
Enrollment: 53
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Does the duration of cardiopulmonary bypass, and aortic cross clamping affects the post operative pulmonary function.

Detailed description: Cardiac surgery usually is done under cardiopulmonary bypass. As the blood contacts with the artificial tubing of the circuit, there is release of mediators which affects pulmonary function. Of no doubt that the duration of cardiopulmonary bypass, and cross clamping time, will affect the spell over of such mediators. Follow up of the pulmonary function, and arterial blood gas is mandatory in such group of patients.

Eligibility criteria: Inclusion Criteria:

* adult patients
* elective open heart surgery

Exclusion Criteria:

* Patients with myocardial ischemia or previous infarction
* low ejection fraction \<30%
* history of AF
* implanted pacemaker
* uncontrolled hypertension
* renal impairment (creatinine \>1.8 mg/dl)
* hepatic dysfunction
* insulin dependent diabetes
* chronic pulmonary disease

Primary outcomes:
measure: quality of oxygenation
timeFrame: 48 hours postoperative
Secondary outcomes:
measure: time to extubation
timeFrame: 24 hours postoperative
measure: ventilation
timeFrame: 48 hours postoperative
measure: carbon dioxide
timeFrame: 48 hours
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Emad Zarief Kamel Said
Study officials:
affiliation: Assiut University
name: Emad Z kamel Said, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06893484: Assessment of Early Pregnancy MAB Completion
Official title: Assessing Completion of Medication Abortion for Very Early Pregnancies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pregnancy
Abortion Early
Keywords: very early pregnancy
pregnancy test
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2025-03-25
Enrollment: 400
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will enroll patients who meet the inclusion criteria at clinical sites in Washington, Georgia, and Maryland.

Brief summary: This is a prospective study to evaluate if successful completion of a medication abortion in patients with very early pregnancy can be detected with a urine pregnancy test at 2 weeks instead of 4 weeks. Additionally, the resolution of pregnancy symptoms in these patients will be characterized. Enrolled participants will take take weekly pregnancy tests and complete weekly questionnaires on their pregnancy symptoms for 4 weeks after their medication abortion.


Eligibility criteria: Inclusion Criteria:

* Pregnant person with early pregnancy ≤42 days
* Eligible and consented to a medication abortion
* Have access to receiving text messages and the internet
* Able to read and understand English

Exclusion Criteria:

- Privacy or safety concerns about filling out the surveys

Primary outcomes:
measure: Proportion of participants with negative high-sensitivity urine pregnancy test at 2 weeks
timeFrame: From time of taking Mifepristone to negative pregnancy test or 4-5 weeks of questionnaires
Secondary outcomes:
measure: Time to resolution of pregnancy symptoms
timeFrame: From time of taking Mifepristone to negative pregnancy test or 4-5 weeks of questionnaires
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Carafem
state: Georgia
city: Chevy Chase
country: United States
facility: Carafem
state: Maryland
city: Renton
country: United States
facility: Cedar River Clinics
state: Washington
Study officials:
affiliation: University of Washington
name: Lyndsey Benson, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01679184: XM-One Study for Living Donor Program
Official title: XM-One Study for Living Donor Program
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Transplant; Failure, Kidney
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2012-09-05
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Living donor kidney transplant recipients

Brief summary: Donor-Specific Antibody (DSA) (HLA) levels and non-HLA antibody levels in recipients prior to living kidney transplantation and randomize these individuals into a desensitization protocol in order to evaluate shifts that can occur with the Luminex and XM-One assay after treatment and up to 6 months post transplant.

If desensitization is needed prior to transplantation in individuals with a negative crossmatch but positive DSA and/or XM-one - patients will be evaluated clinically with routine lab tests (serum creatinine levels, spot urine protein and spot urine creatinine levels) as well as protocol biopsy evaluations.

Detailed description: 1. Rates of acute rejection including subclinical rejection - acute T cell mediated (cellular) rejection, antibody mediated acute rejection, and chronic antibody-associated injury (i.e.: Transplant Glomerulopathy, Chronic allograft arteriopathy) between the groups.
2. Evaluation of endothelial cell activation and injury on biopsies by checking markers for endothelial cell activation and injury (intercellular adhesion molecule-1, ICAM-1/CD54; vascular cell adhesion molecule-1, VCAM-1/CD106; and E-selectin, ELAM-1/CD62E) in two-color stains of tissue with classical endothelial markers (CD34 and Factor VIII).
3. Measurement of serum/plasma levels of TNF-alpha and VEGF and decreased levels of protein C and protein S in the circulation, as an assessment of graft vascular perturbation.
4. Circulating Endothelial Cells (CECs) will be measured by flow cytometry with markers for endothelial cell activation.

Eligibility criteria: Inclusion Criteria:

* Recipients receiving deceased donor transplants.
* Living donor transplant that is T-cell flow crossmatch positive.
* HIV, Hepatitis C and B positive patients.

Exclusion Criteria:

* Pregnant women and children will be excluded from the study.

Primary outcomes:
measure: DSA
timeFrame: 1 year
Secondary outcomes:
measure: DSA
timeFrame: 1 year
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Giselle Guerra, R.N.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06775184: Fiberoptic Bronchoscopy on Supraglottic Airway Devices Position
Official title: The Effect of Fiberoptic Bronchoscopy Examination on Supraglottic Airway Devices Position in Patients Undergoing Elective Surgery
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Supraglottic Airway Devices Position
Keywords: supraglottic device
video laryngeal mask
fiberoptic bronchoscopy
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2025-01-15
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: A comparison of SaCo VLMTM video laryngeal mask airway with the I-gel supraglottic airway during airway management in patients undergoing elective surgery.

Detailed description: The position of the supraglottic airway is checked using a fiberoptic endoscope: The bronchoscope is placed at the opening of the laryngeal mask, and assessed using the following grading system: Grade 1: Vocal cords not visible. Grade 2: Vocal cords and anterior epiglottis visible. Grade 3: Vocal cords and posterior epiglottis visible. Grade 4: Only vocal cords visible.

Eligibility criteria: Inclusion Criteria:

* ASA classification I\~III, age 18\~65 y/o, BMI 18\~30kg/m2, elective surgery, surgery duration \< 2 hours, supine position, general anesthesia with laryngeal mask airway insertion

Exclusion Criteria:

* Smoking, betel nuts use, any known anatomical variation or disease of facial or airway structure, anticipated difficult airway, limited mouth opening distance or neck motility, loosening teeth, gastroesophageal reflux history, ongoing upper airway infection or inflammation symptoms

Primary outcomes:
measure: glottic visualization grades by fiberoptic exam assessment
timeFrame: From anesthesia induction to the end of surgery
Secondary outcomes:
measure: Intra-operative effectiveness
timeFrame: From anesthesia induction to the end of surgery
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02554084: Optical Coherence Tomography of Tear Film Dynamics In-Vivo
Official title: Optical Coherence Tomography of Tear Film Dynamics In-Vivo
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye Disease
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2015-09-18
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate a new instrument that takes digital images of tear film (a thin film that coats the eye that is made up of oil and water). The investigators are interested in measuring how the thickness of the tear film varies through time. The goal is to develop a technique that may enable non-invasive evaluation of Dry Eye Disease for future clinical diagnosis.


Eligibility criteria: Inclusion Criteria:

* Clinically diagnosed Dry Eye Disease
* Normal individuals (those without a dry eye diagnosis and without eye abnormalities)
* Good general health (defined by medication use that has not changed within the last month and the absence of medical conditions that are deemed confounding to the data as determined by the PI)
* Ability to give informed consent
* Willing to spend time for the study
* Either gender
* Any racial or ethnic origin

Exclusion Criteria:

* Use of any prescription ocular medication (such as but not limited to, glaucoma medications and Restasis) used within 14 days of the study visit
* Current eye disease, infection or inflammation that affects the surface of the eye such as, but not limited to blepharitis and ocular allergy
* Past eye surgery, such as, but not limited to, refractive surgery. Subjects who have had cataract surgery less than one year ago
* Use of soft or hard contact lenses 6 hours prior to visit
* Female subjects may not be pregnant or lactating (subjects will be asked to self-report these conditions)
* Infectious diseases (for example, hepatitis, tuberculosis) or an immuno-suppressive disease (for example, HIV) (subjects will be asked to self-report these conditions)

Primary outcomes:
measure: Thickness of lipid layers on patient cornea (nm)
timeFrame: participants will be seen once within a one year period, on average within 1 month
measure: Thickness of aqueous layers on patient cornea (um)
timeFrame: participants will be seen once within a one year period, on average within 1 month
Secondary outcomes:
measure: Thickness maps dynamics
timeFrame: participants will be seen once within a one year period, on average within 1 month
measure: Optical aberrations
timeFrame: participants will be seen once within a one year period, on average within 1 month
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
affiliation: University of Rochester
name: Jannick Rolland, PhD
role: PRINCIPAL_INVESTIGATOR
References: